Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Building Off the Success Seen With Immunotherapy Strategies in NSCLC

May 7th 2021

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Future of SCLC Treatment Lies in Innovative Immunotherapy Combos

May 6th 2021

Ravi Salgia, MD, PhD, discusses pivotal trials that have shaken up the SCLC treatment paradigm and novel immunotherapy regimens under investigation.

Trilaciclib in SCLC: Mechanism of Action and Dosage

May 6th 2021

Jim Schwartz, RPh, provides key insights into the recent approval of trilaciclib and discusses how CDK4/6 inhibition potentially improves response to cytotoxic chemotherapy by protecting patients from myelosuppression.

Quadri Calls for Integration of Surgery Into Evolving Locally Advanced Lung Cancer Paradigm

May 6th 2021

Syed M. Quadri, MD, discusses the role of surgery in early-stage and locally advanced lung cancer, as well future directions with robotic and minimally invasive surgery.

Impact of Myelosuppression in Extensive-Stage SCLC

May 6th 2021

Ralph Boccia, MD, discusses myelosuppression with chemotherapy and highlights its impact on treatment outcomes and patient quality of life.

Frontline Atezolizumab Approved in Europe for PD-L1–High Metastatic NSCLC

May 5th 2021

The European Commission has approved atezolizumab for use as a frontline treatment in patients with metastatic non–small cell lung cancer whose tumors have a high PD-L1 expression and do not harbor EGFR or ALK aberrations.

Decker Details Key Updates in Radiation for Advanced NSCLC

May 5th 2021

Roy Decker, MD, PhD, discusses the utility of interventional radiology and SBRT in patients with oligometastatic disease and detailed ongoing clinical trials for NSCLC as they relate to radiation therapy.

Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

May 4th 2021

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Research Efforts Focus on Reducing Recurrence in Early-Stage EGFR-Mutant NSCLC

May 4th 2021

Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.

Providing Nursing Insight Into the Management of irAEs in Lung Cancer

May 4th 2021

Marianne Davies, NP, DNP, MSN, BSN, discussed the potential severity of immune-related adverse effects and detailed recommended management strategies for patients receiving checkpoint inhibitors, especially in lung cancer.

Molecular Testing Results Are Critical Amid an Expanding Targeted Therapy Paradigm in Advanced NSCLC

May 3rd 2021

Julia K. Rotow, MD, discusses how she approaches molecularly testing in patients with liquid- and tissue-based biopsies, the importance of waiting to initiate immunotherapy until a patient’s molecular testing results are confirmed, and other nuances that she considers when treating patients with advanced non–small cell lung cancer.

Research Efforts Mount With Immunotherapy in Advanced NSCLC

May 3rd 2021

Christopher G. Azzoli, MD, discusses the importance of identifying molecular aberrations prior to starting a patient with advanced non–small cell lung cancer on immunotherapy, ongoing research aimed at furthering the immunotherapy paradigm, and explained why novel biomarkers of response to immunotherapy are needed.

Trilaciclib Tackles Myelosuppression in SCLC

May 1st 2021

Lowell L. Hart, MD, discusses trilaciclib’s unique role in patients with ES-SCLC who experience myelosuppression, as well as the future role of the agent.

Dr. Pacheco on the Mechanism of Action of Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic NSCLC

April 30th 2021

Jose Pacheco, MD, discusses the mechanism of action of trastuzumab deruxtecan in patients with HER2-overexpressing metastatic non–small cell lung cancer.

Dr. Liu on Common NRG1 Fusion Partners in NSCLC

April 29th 2021

Stephen Liu, MD, discusses common NRG1 fusion partners in patients with non–small cell lung cancer.

Dr. Velcheti on the Importance of Real-World Data in NSCLC

April 28th 2021

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

FDA Grants Priority Review to Mobocertinib for Advanced EGFR Exon 20–Mutant NSCLC

April 28th 2021

The FDA has granted a priority review designation to a new drug application for mobocertinib for the treatment of adult patients with EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer, as detected via an FDA-approved assay, who have received previous platinum-based chemotherapy.

Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

April 27th 2021

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.

Trilaciclib Added to NCCN Guidelines for SCLC and Hematopoietic Growth Factors

April 27th 2021

The National Comprehensive Cancer Network® has added the CDK4/6 inhibitor trilaciclib to its Clinical Practice Guidelines in Oncology for small cell lung cancer as well as for supportive care for hematopoietic growth factors.